 |
|
|
| |
Overcoming Barriers and Achieving Optimal Implementation of Cabotegravir and Rilpivirine
Long-Acting (CAB + RPV LA): Staff Study Participant (SSP) Results From the CAB + RPV
Implementation Study in European Locations (CARISEL)
|
| |
| |
Laurence Slama1, María Crusells-Canales2, Julián Olalla Sierra3, Rebecca DeMoor4, Mounir Ait-Khaled5, Samia Dakhia5, Helena Van Mechelen6, Alison Hamilton7,8, Monica Hadi9, Dina Filipenko9, Fiona Brown9, Emma L. Low9, Cassidy A. Gutner10, Maggie Czarnogorski10
1Service d'immuno-infectiologie, Hôtel-Dieu, Paris, France; 2Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; 3Internal Medicine Department, Costa del Sol Hospital, Marbella, Málaga, Spain; 4GlaxoSmithKline, Collegeville, PA, United States; 5ViiV Healthcare, Brentford, United Kingdom; 6ViiV Healthcare, Wavre, Belgium; 7University of California, Los Angeles, CA, United States; 8Center for the Study of Healthcare Innovation, Implementation and Policy, VA Greater Los Angeles Healthcare System, Los Angeles, CA, United States; 9Evidera, London, United Kingdom; 10ViiV Healthcare, Research Triangle Park, NC, United States
|
| |
|
|
|
|
|
